title: Distributions of usage and the costs of conventional medicine and traditional chinese medicine for lung cancer patients in taiwan.
abstract: Background. This study aims to analyze the utilization patterns of patients with lung cancer stratified by surgery status. Methods. A retrospective cohort study was conducted from 1996 to 2010 by using the Longitudinal Health Insurance Database 2005. Results. Among the 7,677 lung cancer patients, 230 (31.17%) and 1,826 (26.32%) who have and have not undergone surgery have used TCM outpatient services, respectively. For lung cancer patients who have not undergone surgery, patients who are aged 70 years and older, males, occupational members, and farmers and fishermen are less likely to avail of TCM services. For lung cancer patients who have undergone surgery, the likelihood of TCM users is higher in residents who used TCM one year prior to lung cancer diagnosis and in patients with insurance amounts ranging from ≥NT$60,000. The total amount paid per visit for WM is higher than that for one year of TCM outpatient care before and after lung cancer diagnosis. Conclusion. The factors associated with TCM use varied according to surgery status. The costs of insurance covering TCM were consistently lower than those covering WM for lung cancer patients. These findings would be useful for health policy makers who are considering TCM and WM integration.
authors: School of Chinese Medicine, China Medical University, Taichung 40402, Taiwan.
authors: Yueh-Hsiang
authors: YH
authors: Liao
authors: Jaung-Geng
authors: JG
authors: Lin
authors: Cheng-Chieh
authors: CC
authors: Lin
authors: Tsai-Chung
authors: TC
authors: Li
references: Toxicol Appl Pharmacol. 2012 May 15;261(1):105-15
references: 22503731
references: BMC Health Serv Res. 2008 Aug 09;8:170
references: 18691428
references: Integr Cancer Ther. 2010 Mar;9(1):16-23
references: 20308084
references: J Cancer Res Clin Oncol. 2011 Jul;137(7):1117-22
references: 21298288
references: J Health Soc Behav. 1995 Mar;36(1):1-10
references: 7738325
references: J Formos Med Assoc. 1994 Mar;93 Suppl 1:S49-55
references: 7920095
references: Diabetes Care. 2006 Nov;29(11):2409-14
references: 17065676
references: BMC Public Health. 2013 Apr 09;13:318
references: 23570503
references: J Gen Intern Med. 2007 Jun;22(6):762-7
references: 17356956
references: Lung Cancer. 2010 May;68(2):137-45
references: 20015572
references: Altern Ther Health Med. 1997 Jul;3(4):40-53
references: 9210775
references: J Altern Complement Med. 2007 Apr;13(3):361-7
references: 17480138
references: Health Aff (Millwood). 2003 May-Jun;22(3):77-88
references: 12757274
references: Eur J Cancer Care (Engl). 2008 Jul;17(4):340-9
references: 18537814
references: BMC Health Serv Res. 2007 Feb 23;7:26
references: 17319950
references: PLoS One. 2013;8(2):e57604
references: 23469033
references: Toxicol Appl Pharmacol. 2011 Aug 1;254(3):221-8
references: 21457722
references: Soc Sci Med. 1996 Nov;43(9):1329-48
references: 8913003
references: BMC Health Serv Res. 2009 Nov 17;9:207
references: 19917139
references: Ann Oncol. 2005 Apr;16(4):655-63
references: 15699021
references: Oncol Nurs Forum. 2003 Sep-Oct;30(5):834-40
references: 12949596
references: BMC Complement Altern Med. 2012 Sep 05;12:146
references: 22947144
references: Zhonghua Yi Xue Za Zhi (Taipei). 2001 Apr;64(4):191-202
references: 11458756
references: Pharmacoepidemiol Drug Saf. 2005 Sep;14(9):651-7
references: 15786515
references: Breast Cancer Res Treat. 2004 Jun;85(3):263-70
references: 15111765
references: Eur J Cancer Care (Engl). 2006 Sep;15(4):397-403
references: 16968323
references: J Altern Complement Med. 2006 May;12(4):379-87
references: 16722788
references: Zhong Xi Yi Jie He Xue Bao. 2009 Apr;7(4):315-24
references: 19361360